About The Study: In this post hoc pooled analysis of 13,194 patients with chronic heart failure (HF) in the PARADIGM-HF and PARAGON-HF randomized clinical trials, sacubitril/valsartan significantly reduced hospitalization for any reason, with benefits most apparent in patients with a left ventricular ejection fraction below normal. This reduction appeared to be principally driven by lower rates of cardiac and pulmonary hospitalizations.
About The Study: In this post hoc pooled analysis of 13,194 patients with chronic heart failure (HF) in the PARADIGM-HF and PARAGON-HF randomized clinical trials, sacubitril/valsartan significantly reduced hospitalization for any reason, with benefits most apparent in patients with a left ventricular ejection fraction below normal. This reduction appeared to be principally driven by lower rates of cardiac and pulmonary hospitalizations.
Corresponding Author: To contact the corresponding author, Muthiah Vaduganathan, MD, MPH, email mvaduganathan@bwh.harvard.edu.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamacardio.2024.2566)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the European Society of Cardiology Congress 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA Cardiology
Discover more from Science
Subscribe to get the latest posts sent to your email.
